SCHEDULES
F1SCHEDULE 12AFurther provision as to the performance of pharmacovigilance activities
PART 8Periodic safety update reports
Format of periodic safety update reports27
1
Electronic PSURs must be submitted in the following format—
a
Part I: title page including signature;
b
Part II: executive summary; and
c
Part III: table of contents which contains—
i
introduction,
ii
worldwide marketing authorisation status,
iii
actions taken in the reporting interval for safety reasons,
iv
changes to reference safety information,
v
estimated exposure and use patterns—
aa
cumulative subject exposure in clinical trials,
bb
cumulative and interval patient exposure from marketing experience,
vi
data in summary tabulations—
aa
reference information,
bb
cumulative summary tabulations of serious adverse events in clinical trials,
cc
cumulative and interval summary tabulations from post-marketing data sources,
vii
summaries of significant findings from clinical trials during the reporting interval—
aa
completed clinical trials,
bb
ongoing clinical trials,
cc
long-term follow-up,
dd
other therapeutic use of medicinal product,
ee
new safety data related to fixed combination therapies,
viii
findings from non-interventional studies,
ix
information from other clinical trials and sources,
x
non-clinical data,
xi
literature,
xii
other periodic reports,
xiii
lack of efficacy in controlled clinical trials,
xiv
late-breaking information,
xv
overview on signals: new, ongoing or closed,
xvi
signal and risk evaluation—
aa
summaries of safety concerns,
bb
signal evaluation,
cc
evaluation of risks and new information,
dd
characterisation of risks, and
ee
effectiveness of risk minimisation (if applicable),
xvii
benefit evaluation—
aa
important baseline efficacy and effectiveness information,
bb
newly identified information on efficacy and effectiveness, and
cc
characterisation of benefits,
xviii
integrated benefit-risk analysis for authorised indications—
aa
benefit-risk context: medical need and important alternatives, and
bb
benefit-risk analysis evaluation,
xix
conclusions and actions, and
xx
appendices to the PSUR.
2
In this paragraph, “signal evaluation” means the process of further evaluating a validated signal taking into account all available evidence, to determine whether there are new risks causally associated with the active substance or medicinal product, or whether known risks have changed, and that process—
a
may include non-clinical and clinical data; and
b
must be as comprehensive as possible regarding the sources of information used for that process.
Sch. 12A inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 6 (as amended by S.I. 2019/1385, reg. 1, Sch. 1 para. 9 and S.I. 2020/1488, reg. 1, Sch. 2 para. 192); 2020 c. 1, Sch. 5 para. 1(1)